Items tagged with Treatment
Public call for experts with experience in the co-administration of treatment for drug-resistant TB and hepatitis C (post)
A recent systematic review, commissioned by the World Health Organization (WHO), demonstrated that the prevalence of chronic hepatitis C virus (HCV) infection is high among patients with TB. Published evidence on the safety and effectiveness of co-administering treatment for rifampicin-resistant TB and HCV co-infection is extremely scarce and insufficient as a basis to develop global policy recommendations on this intervention.
Real-world management and outcomes of U.S. patients treated with BPaL for rifampin-resistant TB (post)
In a recent study published in the journal Clinical Infectious Diseases, researchers reported on the treatment of rifampin-resistant tuberculosis in the United States (U.S.) using the Food and Drug Administration (FDA) approved bedaquiline, pretomanid, and linezolid (BPaL) therapy.
The ABC for a TB Activist: 1/4/6×24 Campaign and supportive diagnostics (post)
On 15 June, 2023, TB Europe Coalition (TBEC) organized a webinar featuring a presentation by Treatment Action Group’s TB Project Officer, David Branigan, on the practical actions advocates can take to promote the adoption and scale up of shorter, safer 1/4/6 regimens for TB prevention and the treatment of drug-sensitive and drug-resistant TB as well as supportive diagnostics. The webinar discusses specific advocacy strategies to ensure these regimens and diagnostics are included in Global Fund proposals as well as in National Strategic Plans, to promote increased availability and access in countries. This webinar is part of the TBEC webinar series: The ABC for a TB Activist.
Eradicating deadly TB with better tests and treatments (post)
Dr Cristina Vilaplana is a medical doctor passionate about helping patients with tuberculosis (TB). Her research could make a difference to a lot of people.
Once-daily dolutegravir sufficient when taking TB treatment (post)
A second daily dose of dolutegravir for people taking standard TB treatment seems to be unnecessary, a South African randomised study has reported in the journal Lancet HIV.
Beyond expectations: study finds treatment success gap in drug-resistant TB (post)
In a recent study published in the Journal of Infection, researchers performed a systematic literature review of global treatment outcomes of extensively drug-resistant Tuberculosis.
Investigational three-month TB regimen is safe but ineffective, NIH study finds (post)
The first clinical trial of a three-month TB treatment regimen is closing enrollment because of a high rate of unfavorable outcomes with the investigational course of treatment.
Why hunger is driving thousands to abandon the drugs that keep them alive (post)
Crippling hunger has driven Vitola Genti to the brink. The 67-year-old, a refugee in Malawi, has HIV and is dependent on antiretroviral drugs to keep the virus dormant in her body.
Increased risk of all-cause mortality in co-occurring diabetes, HIV during TB treatment (post)
Mortality risk was higher for patients with concurrent diabetes and TB infection and more common than HIV and TB coinfection.
TB therapy: Smallest particles will deliver the drug to the lungs in future (post)
KIT and Research Center Borstel present nanoparticles with a high antibiotic concentration for inhalation – nanocarriers of antibiotics can reduce resistances and enhance compatibility
Page 70 of 108 · Total posts: 0
←First 69 70 71 Last→